N/A N=288 Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology
Infection Associated With Catheter · Urinary Tract Infection
Primary: Urinary Tract Infection Rate — 24; 29 Participants — p=0.30
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=121 Hydrocodone For Pain Control in First Trimester Surgical Abortion
Pain
Primary: Patient Perception of Pain — 65.7; 63.1 mm
Phase 2 N=47 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
Recurrent Uveal Melanoma · Stage III Uveal Melanoma AJCC v7 · Stage IIIA Uveal Melanoma AJCC v7
Primary: Proportion of Patients Without a Progression Free Survival Event at 4 Months (PFS4) — .323; .267 proportion of participants — p=0.70
N/A N=48 Auto Bilevel Adherence Following a Poor Initial Encounter With Continuous Positive Airway Pressure (CPAP)
Obstructive Sleep Apnea
Primary: Group Compliance of the Auto Bilevel Group Compared to the CPAP Group Measured by Average Nightly Use. — 284.7; 255.1 minutes/night — p=0.377
Phase 4 N=479 Safety of Nasal Influenza Immunisation in Children With Asthma
Asthma
Primary: Change in Asthma Symptoms and Control Pre and 4 Weeks Post LAIV, as Assessed by Validated Questionnaire — 28; 254; 37 Participants — p=0.26
Phase 4 N=20 Immune Response Following Seasonal Influenza Vaccination
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
N/A N=31 Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome
Hyperphagia · Prader-Willi Syndrome
Primary: Amplitude of Eyeblink Startle Responses — 0.006; 0.001; 0.008; 0.001 microvolts
Phase 3 N=216 Methotrexate and Mycophenolate Mofetil for UVEITIS
Uveitis
Primary: Number of Participants Achieving Treatment Success at 6 Months (Phase I, 0-6 Months) — 64; 56 Participants
Phase 2 N=44 Magnesium Supplements In The Treatment Of Pseudoxanthoma Elasticum (PXE)
Pseudoxanthoma Elasticum
Primary: Von Kossa Staining Per Unit Area of Dermis — -0.0033; 0.0010; 0.0087; 0.0123 microns
Phase 4 N=623 A Comparative Effectiveness RCT of Optimized Cessation Treatments
Smoking Cessation
Primary: Number of Participants With Abstinence From Smoking — 19; 49 Participants — p=<.001
Phase 2 N=33 Study of SOR007 Ointment for Actinic Keratosis
Actinic Keratosis
Primary: Number of Participants With Treatment Emergent Adverse Events — 2; 1; 3; 1 Participants
N/A N=2,862 The Respiratory Protection Effectiveness Clinical Trial
Influenza · Respiratory Syncytial Viruses · Paramyxoviridae Infections
Primary: Protective Effects of N95 Respirators vs Medical Masks (MM) as Assessed by Number of Influenza A and B Events — 222; 204 number of influenza A and B events
N/A N=134 Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery
Analgesia, Obstetrical · Obstetric Surgical Procedures
Primary: NRS Score for Pain (0-10) With Movement 24 Hours After Spinal Administration — 4; 3 score on a scale — p=0.132
N/A N=44 Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders
Sleep Disordered Breathing · Sleep Apnea, Central
Primary: Apnea-Hypopnea Index (AHI) — 38; 13; 12 events per hour — p=.001
Phase 2 N=118 Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay
Cesarean Section
Primary: Discharge on Postoperative Day #2 — 5; 2 Participants